

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on October 19, 2006.

SUBMISSION OF SEQUENCE LISTING  
UNDER 37 CFR §§1.821-1.825  
Patent Application  
Docket No. ARS-122  
Serial No. 10/570,122

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christine Power, Yan Lavrovsky  
Serial No. : 10/570,122  
Filed : February 28, 2006  
Conf. No. : 7430  
For : Treatment of Fibrotic Disease

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825


Sir:

Transmitted herewith is a Sequence Listing in computer readable format under 37 CFR §§1.821 through 1.825 for the above-identified patent application. The paper copy of the Sequence Listing was submitted with the application when filed. A Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures was received from the Patent and Trademark Office which indicated that the subject application does not comply with the sequence requirements of 37 CFR §§1.821-1.825. A copy of the Notification is enclosed herewith.

I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Enclosures: Sequence listing in computer readable format; Copy of Notification to Comply with Requirements